MX2015002038A - Pirazoles sustituidos como bloqueadores del canal de calcio tipo n. - Google Patents

Pirazoles sustituidos como bloqueadores del canal de calcio tipo n.

Info

Publication number
MX2015002038A
MX2015002038A MX2015002038A MX2015002038A MX2015002038A MX 2015002038 A MX2015002038 A MX 2015002038A MX 2015002038 A MX2015002038 A MX 2015002038A MX 2015002038 A MX2015002038 A MX 2015002038A MX 2015002038 A MX2015002038 A MX 2015002038A
Authority
MX
Mexico
Prior art keywords
calcium channel
channel blockers
type calcium
substituted pyrazoles
pyrazoles
Prior art date
Application number
MX2015002038A
Other languages
English (en)
Inventor
Zhihua Sui
Christopher Flores
Nalin Subasinghe
Mark Wall
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49036655&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015002038(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2015002038A publication Critical patent/MX2015002038A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula (I), (Ver formula) en donde X1, X2, X3, X4, R1, R2, R3, y Q son como se definen en la presente descripción, útiles como bloqueadores del canales de calcio tipo N.
MX2015002038A 2012-08-16 2013-08-16 Pirazoles sustituidos como bloqueadores del canal de calcio tipo n. MX2015002038A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261683777P 2012-08-16 2012-08-16
PCT/US2013/055271 WO2014028803A1 (en) 2012-08-16 2013-08-16 Substituted pyrazoles as n-type calcium channel blockers

Publications (1)

Publication Number Publication Date
MX2015002038A true MX2015002038A (es) 2016-01-22

Family

ID=49036655

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002038A MX2015002038A (es) 2012-08-16 2013-08-16 Pirazoles sustituidos como bloqueadores del canal de calcio tipo n.

Country Status (19)

Country Link
US (1) US8901314B2 (es)
EP (1) EP2885293B1 (es)
JP (2) JP2015524852A (es)
KR (1) KR20150042834A (es)
CN (2) CN104903316B (es)
AU (2) AU2013302471B2 (es)
BR (1) BR112015003395A2 (es)
CA (1) CA2882123C (es)
CL (1) CL2015000358A1 (es)
CR (1) CR20150069A (es)
EA (1) EA201590380A1 (es)
ES (1) ES2600743T3 (es)
HK (1) HK1214860A1 (es)
IL (1) IL237191A0 (es)
MX (1) MX2015002038A (es)
PE (1) PE20151140A1 (es)
PH (1) PH12015500315A1 (es)
SG (1) SG11201501137VA (es)
WO (1) WO2014028803A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9974775B2 (en) 2013-08-16 2018-05-22 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014028800A1 (en) 2012-08-16 2014-02-20 Janssen Pharmaceutica Nv Substituted pyrazoles as n-type calcium channel blockers
EP3307068B1 (en) 2015-06-12 2021-08-25 Vettore, LLC Mct4 inhibitors for treating disease
KR101743960B1 (ko) 2015-07-06 2017-06-08 서울대학교산학협력단 G단백질 결합형 수용체19 작용제를 유효성분으로 함유하는 알츠하이머 질환 또는 치매를 예방, 치료 또는 지연하기 위한 약학적 조성물
TW201718557A (zh) * 2015-10-08 2017-06-01 歌林達有限公司 經吡唑基取代之四氫吡喃基碸
TW201726128A (zh) * 2015-10-08 2017-08-01 歌林達有限公司 經吡唑基取代之四氫哌喃基碸
US10329321B2 (en) * 2016-02-09 2019-06-25 Alexander Krantz Site-selective functionalization of proteins using traceless affinity labels
KR102573333B1 (ko) 2016-06-28 2023-08-31 삼성디스플레이 주식회사 표시 장치
US10214492B2 (en) * 2016-12-12 2019-02-26 Vettore, LLC Heterocyclic inhibitors of MCT4
US11400165B2 (en) 2017-11-04 2022-08-02 Advanced Proteome Therapeutics Inc. Composition and method for modifying polypeptides
JP6800492B2 (ja) * 2018-06-29 2020-12-16 ＭｉＺ株式会社 水素を含む癌性疼痛の抑制もしくは軽減のための組成物
WO2024036243A2 (en) * 2022-08-10 2024-02-15 Vettore, LLC Salts of heterocyclic inhibitors of monocarboxylate transporter 4 for the treatment of disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US6117841A (en) * 1997-05-30 2000-09-12 Warner-Lambert Company Substituted peptidylamine calcium channel blockers
WO2002005799A2 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
JP4537855B2 (ja) * 2002-10-09 2010-09-08 久光製薬株式会社 抗真菌活性を有する新規ピラゾール化合物
BRPI0410871A (pt) * 2003-05-30 2006-07-04 Neuromed Tech Inc 3-aminometil-pirrolidinas como bloqueadores do canal de cálcio do tipo n
EP1965799A2 (en) * 2005-12-22 2008-09-10 Merck & Co., Inc. Substituted piperidines as calcium channel blockers
CA2718017C (en) * 2008-03-11 2017-10-10 Danisco Us Inc. Glucoamylase and buttiauxiella phytase during saccharification
EP2676956A1 (en) * 2008-08-01 2013-12-25 Purdue Pharma L.P. Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
KR101052065B1 (ko) * 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9974775B2 (en) 2013-08-16 2018-05-22 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers

Also Published As

Publication number Publication date
EP2885293B1 (en) 2016-07-27
EP2885293A1 (en) 2015-06-24
AU2013302471A1 (en) 2015-02-26
AU2013302471B2 (en) 2017-08-17
CA2882123A1 (en) 2014-02-20
CN107857757A (zh) 2018-03-30
JP6294559B1 (ja) 2018-03-14
US8901314B2 (en) 2014-12-02
BR112015003395A2 (pt) 2017-07-04
JP2015524852A (ja) 2015-08-27
KR20150042834A (ko) 2015-04-21
PE20151140A1 (es) 2015-08-07
CA2882123C (en) 2021-07-20
ES2600743T3 (es) 2017-02-10
PH12015500315A1 (en) 2015-03-30
CN104903316B (zh) 2017-11-28
CL2015000358A1 (es) 2015-06-12
IL237191A0 (en) 2015-04-30
HK1214860A1 (zh) 2016-08-05
WO2014028803A1 (en) 2014-02-20
SG11201501137VA (en) 2015-04-29
JP2018065865A (ja) 2018-04-26
CR20150069A (es) 2015-05-18
AU2017261551B2 (en) 2019-07-04
AU2017261551A1 (en) 2017-12-07
US20140163031A1 (en) 2014-06-12
EA201590380A1 (ru) 2015-07-30
CN104903316A (zh) 2015-09-09

Similar Documents

Publication Publication Date Title
MX2015002038A (es) Pirazoles sustituidos como bloqueadores del canal de calcio tipo n.
IN2015DN00960A (es)
PH12014502697B1 (en) New diazaspirocycloalkane and azaspirocycloalkane
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
PH12015500316A1 (en) Substituted pyrazoles as n-type calcium channel blockers
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
UA111626C2 (uk) Похідні дигідрохінолін-2-ону
CR20150271A (es) Peptidos como agonistas de oxitocina
MX361499B (es) Baricitinib deuterado.
IN2015DN00598A (es)
MX2012008141A (es) Compuestos y metodos.
CR20150084A (es) 2-oxo-2,3-dihidro-indoles
PH12015500310A1 (en) Pyrrolopyrazoles as n-type calcium channel blockers
PH12017500447A1 (en) Triazole compounds as t-type calcium channel blockers
MX2015014470A (es) Analogos de combretastatina.
MX2016006807A (es) Derivados de imidazol.
PH12015500314A1 (en) Cyclopentylpyrazoles as n-type calcium channel blockers
IN2015DN02244A (es)
IN2013MU03015A (es)
MX2016002043A (es) Imidazoles sustituidos como bloqueadores de canales de calcio tipo n.
MX2013013021A (es) Nuevos compuestos de hexahidropirroloimidazolona.
MX2015009377A (es) Compuestos radiomarcados.
MX2014008856A (es) Derivados de imidazolilcetona como inhibidores de aldosterona sintasa.
IN2015DN01285A (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal